Regentis Biomaterials Ltd. RGNT
1.98
(0.06)
(2.94%)
as of 25 Sep
- Market cap
- $15.8M
- P/E
- —
Follow RGNT
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
5.62 | 2.65 | 0.05 | 0.07 |
+1 more quarter Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 15.71% | 1,718.74% | 1,025.93% | |
Debt/Equity |
0.00 | 0.25 | (0.18) | (0.12) | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(6.60) | 0.00 | — | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.84) | (1.37) | (0.34) | (0.64) | |
Working Capital |
7.64 | 4.74 | (9.23) | (6.01) | |
Capital Expenditures |
(0.03) | 0.00 | — | 0.00 | |
Net Current Asset Value |
7.62 | 4.74 | (44.33) | (41.10) | |
| Other line items | |||||
Quick Ratio |
5.42 | 2.57 | 0.02 | 0.04 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Payables |
0.27 | — | — | — | |
Average Assets |
4.86 | — | — | — | |
Average Common Equity |
(19.11) | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates